CAP satellite symposiums are live educational programs with CME funded through a grant by an exhibitor and independently organized by a third party.

Monday, October 22

Personalized Medicine in Oncology enabled by Next-Generation Sequencing

Time: 6:30 pm

This 1.5 hours satellite symposium will provide the learner with an introduction to Genomics and a quick overview of Next-Generation Sequencing (NGS) to better understand the technology that allows sequencing of DNA/RNA much more quickly. The presentation will include specific oncology applications including tumor mutational burden, tumor profiling as it applies to colorectal cancer, and microsatellite instability (MSI), the condition of genetic predisposition to mutation that results from impaired DNA mismatch repair (MMR). The presence of MSI represents that MMR is not functioning normally. It will conclude with a review of the human microbiome, which covers all microbes genes, and immunotherapy.

Program Objectives

  • Define how genomics and knowledge of DNA has impacted patient care
  • Review the broad range of applications and experiments that can be performed with NGS
  • Discuss how microsatellite instability and tumor mutational burden test results can help with immunotherapy decisions

CME Accreditation and Designation Statements
EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

EXCEL Continuing Education designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This satellite symposium is supported through an educational grant from ILLUMINA.

Register for this symposium

Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do

Registration and Dinner: 6:00 PM
Time: 6:30 PM – 8:00 PM

Chair and Presenter:
Lynette M. Sholl, MD
Associate Pathologist
Brigham and Women’s Hospital
Associate Professor, Pathology
Harvard Medical School
Boston, Massachusetts

Registration and Dinner: 6:00 PM
Symposium: 6:30 PM – 8:00 PM

To register, please visit: www.peerview.com/testEGFR

With the rapid pace of progress in the fields of oncology and pathology, molecular profiling is becoming an integral tool for guiding individualized management of an increasing number of cancers, including lung cancer. Testing to identify EGFR and other key driver mutations is considered essential in advanced NSCLC, and the latest guidelines offer evidence-based recommendations for implementing this in everyday practice. Still, questions remain about the best testing methodologies and workflows to use throughout the continuum of advanced disease. The recent emergence of new, practice-changing data in advanced EGFR-mutant NSCLC and shifts in the treatment landscape also have far-reaching implications for both pathology and oncology practice in terms of what, when, and how to test. Join PeerView Live and our expert-led panel to learn more about the progress in testing and treatment of EGFR-mutant NSCLC, and what this means for pathologists working in various settings.

Upon completion of this activity, participants should be better able to:

  • Describe molecular pathways that drive malignancy in lung cancer and oncogenic activation of tyrosine kinases, such as mutations in the EGFR, that have led to the development of specific targeted molecular treatments
  • Evaluate current research related to EGFR mutations in the settings of newly diagnosed NSCLC and acquired resistance in the context of the evolving treatment landscape
  • Assess the latest clinical data on EGFR-targeted therapy in NSCLC throughout the continuum of disease from the first-line setting to the second-line setting and beyond
  • Discuss the evolving science and recommendations for molecular testing in lung cancer, including the use of tissue- and blood-based biomarker testing for evaluation of EGFR mutation status in advanced/metastatic NSCLC in newly diagnosed patients and those with acquired resistance following prior EGFR TKI therapy
  • Implement best practices for optimal molecular testing for evaluation of EGFR mutations and interpretation of results to guide treatment decisions throughout the disease continuum of advanced/metastatic NSCLC

Providership, Credit and Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Molecular Testing for EGFR Mutations in the Context of a Changing Treatment Landscape, Evolving Testing Options, and New Guidelines: What Pathologists Need to Know and Do has been registered as a Lifelong Learning (Part II) to offer 1.5 credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath MOC credit. Participation information will be shared with ABPath through the ACCME’s Program Reporting and Activity System (PARS). Individual or aggregated participant data may be shared with the funder of the activity

Providership
This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support
This activity is supported by an independent educational grant from AstraZeneca.

Tuesday, October 23

Assessing RET-Altered Tumors: An Increasingly Important Target For Personalized Oncology Care

Registration and Dinner: 6:00 PM – 6:30 PM
Satellite: 6:30 PM – 8:00 PM

It is well-known that point mutations and gene rearrangements/fusions in RET can drive oncogenesis in various solid tumors. However, exciting new data have emerged that suggest selective RET inhibitors have promising anti-tumor activity in patients with these alterations. A critical component of personalized cancer care requires that pathologists understand these new data and, more importantly, are equipped to detect RET alterations so that appropriate patients are offered treatment and enrollment on clinical trials that can improve their clinical outcomes.
This interactive symposium will serve as an ideal forum for attendees to directly engage with and learn from leading pathology experts. Symposium attendees will be provided with a networked all-in-one handheld device that enables them to fully interact, text, and contribute to the symposium cases. This program is designed to provide pathologists insights on the application of the latest clinical data on selective RET inhibitors along with practical guidance to facilitate the detection of RET alterations.

Program Objectives

  • Discuss the concept of “oncogene addiction” and the dependency on a single activated kinase for proliferation and survival in RET fusion cancers and RET-mutant MTC
  • Describe the rationale for reflexive testing of RET in lung and thyroid tumors
  • Select evidence-based testing strategies to detect RET fusions and mutations
  • Tailor patient treatment protocols using RET inhibitors as part of a multidisciplinary team collaboration

Accreditation
Physician Continuing Medical Education

Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation
Postgraduate Institute for Medicine designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity is supported by an educational grant from Loxo Oncology.

Register for this symposium

The Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle
Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies

Registration and Dinner: 6:00 PM
Symposium: 6:30 PM – 8:00 PM

To register, please visit: www.peerview.com/biomarkers18

The cancer immunotherapy arsenal continues to expand, and it has become clear that biomarkers are needed to identify patients who are most likely to benefit from specific agents or immune-based combinations. In the context of a rapid shift towards precision immuno-oncology, pathologists have an important role to play in implementing biomarker testing and interpreting the results to help guide clinical decisions.

What’s the state of the evidence on cancer immunotherapies across the oncologic and hematologic spectrum? How can we improve testing for PD-L1 expression and MSI/MMR status in current practice? Is TMB testing ready for prime time, and what challenges must be overcome to achieve its widespread implementation? What new biomarker strategies are on the horizon? And how can pathologists and oncologists effectively work together to realize the potential of precision immuno-oncology? All of these topics and many more will be addressed by our panel of pathology and oncology experts in this highly visual and interactive CME- and MOC-certified live learning session and tumor board.

Upon completion of this activity, participants should be better able to:

  • Characterize the efficacy/safety profiles and clinical roles of the current and emerging immunotherapies and combinations (eg, those targeting PD-1/PD-L1, CTLA-4, LAG-3, etc) across the spectrum of solid and liquid cancers
  • Describe evidence supporting the use of PD-L1, MSI/MMR, TMB, and other promising biomarkers as predictors of benefit from cancer immunotherapies
  • Discuss practical aspects of immunotherapy biomarker testing and interpretation, including benefits/limitations of different testing methodologies, assays, cut-points, and other nuances
  • Assess the potential role of novel strategies and technologies being evaluated as part of cancer immunotherapy biomarker development for predictive and other purposes
  • Implement best practices for cancer immunotherapy biomarker testing in community and academic settings based on the latest evidence and recommendations
  • Establish effective strategies for interdisciplinary collaboration among pathologists, oncologists, and other key professionals regarding biomarker testing and interpretation to guide decisions about the use of cancer immunotherapies and combinations in patients with cancer

Providership, Credit, and Support
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

The activity title “Central Role of Biomarker Testing in Piecing Together the Immuno-Oncology Puzzle: Essential Guidance for Pathologists to Maximize the Potential of Cancer Immunotherapies” has been registered as a Lifelong Learning (Part II) to offer 1.5 credits in the American Board of Pathology’s (ABPath) Continuing Certification program. It is the CME/MOC activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABPath MOC credit. Participation information will be shared with ABPath through the ACCME’s Program Reporting and Activity System (PARS). Individual or aggregated participant data may be shared with the funder of the activity.

Providership
This CME/MOC activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support
This activity is supported through independent educational grants from AstraZeneca, Bristol-Myers Squibb, and Foundation Medicine, Inc.